Alicaforsen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Alicaforsen
Accession Number
DB06224
Type
Small Molecule
Groups
Investigational
Description
Not Available
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Alicaforsen sodium4TWN6SZB8W331257-52-4Not applicable
Categories
UNII
J8435V445B
CAS number
185229-68-9
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in crohn's disease and ulcerative colitis.

Pharmacodynamics
Not Available
Mechanism of action

Alicaforsen selectively inhibits ICAM‑1 gene expression. Over-expression of ICAM‑1 occurs in a wide variety of inflammatory disorders, including ulcerative colitis (UC), pouchitis and tissues in the eye, gastrointestinal teact, lungs and skin. UC is an inflammatory bowel disease of the colon, a part of the large intestine, and pouchitis is an inflammation of the surgically constructed internal pouch created in UC patients when their diseased colons are removed. [ISIS Pharmaceutical Website] Alicaforsen is a RNase H dependent phosphorothioate-modified antisense oligodeoxynucleotide inhibitor which shuts down specific sequences of intracellular adhesion molecule 1 (ICAM1) mRNA and thus production of ICAM1, which prevents the inflammatory response. ICAM is a cell surface glycoprotein (immunoglobulin superfamily) which facilitates leukocyte adhesion and antigen presentation in the intestinal mucosa. Alicaforsen hybridizes the oligonucleotide strand with the target mRNA to suppress expression of ICAM1.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK: Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther. 2006 May 15;23(10):1427-34. [PubMed:16669957]
  2. Gewirtz AT, Sitaraman SV: Technology evaluation: alicaforsen (Isis). Curr Opin Mol Ther. 2005 Jun;7(3):273-81. [PubMed:15977426]
  3. Fefferman DS, Farrell RJ: Making sense of antisense: ISIS 2302 (alicaforsen) in the treatment of pouchitis. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchits. Inflamm Bowel Dis. 2004 Jul;10(4):487-8. [PubMed:15475766]
  4. Link [Link]
External Links
Wikipedia
Alicaforsen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingBasic ScienceInflammatory Bowel Diseases (IBD)1
2CompletedTreatmentUlcerative Colitis (UC)2
3Active Not RecruitingTreatmentPouchitis1
3CompletedTreatmentCrohn's Disease (CD)1
3Unknown StatusTreatmentCrohn's Disease (CD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:17 / Updated on November 02, 2018 09:01